ReviewAnnals of medicine2026
What do we know about redox status? A review in neonates of mothers with preeclampsia.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia (PE) is a leading cause of maternal and perinatal morbimortality worldwide, driven by oxidative stress from an imbalance between reactive oxygen and nitrogen species and antioxidant defenses. Neonates born to mothers with PE face an oxidized intrauterine environment, yet their antioxidant response and potential therapeutic strategies remain insufficiently characterized.
methodsA literature review was conducted searching PubMed, Redalyc, CORE, and Google Scholar for English-language papers using keywords including oxidative stress, preeclampsia, neonatal outcomes, antioxidant defence, NRF2, polysulfides, and antioxidant supplementation.
resultNeonates from mothers with PE exhibit elevated lipid peroxidation markers (conjugated dienes, lipohydroperoxides, malondialdehyde) yet show compensatory increases in total antioxidant capacity. The neonate's antioxidant defense system is summarized, including its enzymatic components superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), and non-enzymatic factors, with a particular focus on novel reducing molecules known as polysulfides. Investigation into persulfides and polysulfides is not merely supplementary but essential, as these emerging redox species represent a promising and potentially superior therapeutic frontier for mitigating oxidative damage. The article also discusses contradictory findings on the impact of antioxidant interventions for PE, highlighting the inherent challenges of clinical trials in this population. We examine the potential therapeutic role of the transcription factor NRF2, alongside concerns about possible side effects.
conclusionsCurrent antioxidant supplementation for PE has proven largely ineffective or harmful. Persulfides and polysulfides emerge as a potentially superior antioxidant frontier for neonatal protection, warranting dedicated investigation. Well-designed clinical trials are urgently needed to evaluate the safety and efficacy of novel antioxidant strategies for improving neonatal outcomes in PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.